The Drugs Controller General of India DCGI has granted permission for the emergency use of therapeutic application of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule & analogue of glucose, it can be easily produced & made available in plenty informed Defence Research and Development Organisation DRDO.
The drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddyâ€™s Laboratories, Hyderabad.
The results of the third phase of the clinical trial of the drug showed that the molecule helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion, said the report.